Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box: 1415-111, Tehran, Iran.
Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
BMC Complement Med Ther. 2020 Apr 19;20(1):116. doi: 10.1186/s12906-020-02908-5.
Gestational diabetes mellitus (GDM) is one the most common complications of pregnancy. The present work aimed at investigating the effect of ginger on the blood glucose level of GDM women with impaired glucose tolerance test (GTT).
This randomized double-blind placebo-controlled clinical trial was performed on the total of 70 women with GDM, who were in 24-28 weeks of pregnancy with impaired GTT from 2015 to 2016. For this purpose, the women were assigned to two groups of ginger or placebo. The ginger group received 126 tablets of ginger, and the placebo group received 126 tablets of placebo for six weeks. The serum Blood Sugar 2 h post-prandial (BS2hpp), Fast Blood Sugar (FBS) and insulin, as well as Homeostasis Model Assessment (HOMA) index were analyzed before and six weeks after intervention.
The mean of FBS (P = 0.04), fasting insulin (P = 0.01), and HOMA index (P = 0.05) was reduced significantly in the ginger group six weeks after intervention in comparison to the placebo group. But the mean of BS2hpp did not show any significant reduction in the two groups (P > 0.05(.
Oral administration of ginger tablet improved FBS, serum insulin and HOMA index in the women with GDM; however, it could not reduce their BS2hpp level. The trial has been registered in the Iranian Registry of Clinical Trials (IRCT2015090523897N1).
妊娠期糖尿病(GDM)是妊娠最常见的并发症之一。本研究旨在探讨生姜对葡萄糖耐量试验(GTT)受损的 GDM 妇女血糖水平的影响。
这项随机双盲安慰剂对照临床试验于 2015 年至 2016 年期间在 70 名患有 GDM 的女性中进行,这些女性处于妊娠 24-28 周,GTT 受损。为此,将这些女性分为生姜组或安慰剂组。生姜组服用 126 片生姜,安慰剂组服用 126 片安慰剂,共 6 周。干预前后分析血清餐后 2 小时血糖(BS2hpp)、空腹血糖(FBS)和胰岛素以及稳态模型评估(HOMA)指数。
干预 6 周后,与安慰剂组相比,生姜组的 FBS(P=0.04)、空腹胰岛素(P=0.01)和 HOMA 指数(P=0.05)均显著降低。但两组的 BS2hpp 均值均无明显降低(P>0.05)。
生姜片口服可改善 GDM 妇女的 FBS、血清胰岛素和 HOMA 指数,但不能降低其 BS2hpp 水平。该试验已在伊朗临床试验注册中心(IRCT2015090523897N1)注册。